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Virginia M. Miller, PhD, Rochester, Minn. 
Purpose: Experiments were designed to characterize ndothelin receptors in human 
varicose veins. Three groups of veins were studied: (1) varicose vein (VV) tributaries of 
the greater saphenous vein from patients who were undergoing vein stripping for primary 
varicosity; (2) greater saphenous veins (SVs) from the same patients; and (3) greater 
saphenous veins from patients without varicosity who were undergoing arterial recon- 
struction (control). 
Methods: Veins were either cut into rings and suspended in organ chambers for measure- 
ment of isometric force, prepared for receptor binding of membrane proteins, or were 
prepared for measurement of preproendothelin mRNA by reverse transcriptase-poly- 
merase chain reaction (RT-PCR). 
Results: Endothelin-1 (10 -11 to 10 -r tool/L) produced similar concentration-dependent 
contractions in rings with or without endothelium. Maximal tensions were significantly 
greater in control veins compared with either SVs or Ws .  Sarafotoxin $6c (10 -1~ to 3 x 
10 -7 mol/L), which is selective for the endothelin-B receptor, also produced concentra- 
tion-dependent i creases in tension in all veins. Sarafotoxin $6c responses in VVs were 
shifted significantly rightward compared with either SVs or control. Maximal tensions to 
sarafotoxin $6c also were significantly greater in control veins compared with either SVs 
or VVs. In receptor binding studies, the number of binding sites as defined by competi- 
tive inhibition of 12SI-endothelin-1 byendothelin-1 was less in VVs than control veins. 
Competitive inhibition of 125I-endothelin-1 with endothelin-3 (both A and B receptors) 
or sarafotoxin $6c (B receptors only) suggests that the difference in receptor number 
between varicose and nonvaricose veins is attributable to differences in the endothelin-B 
receptor subtype. Binding affinities were not significantly different for either of the 
receptor subtypes in all veins studied. Preproendothelin mRNA as quantitated by RT- 
PCR tended to be higher in VVs compared with either SVs or control veins. 
Conclusions: Decreased contractions toendothelin-1 in both varicose and saphenous veins 
of patients with primary varicosity may be associated with a decrease in the number of 
receptors. These receptors may be downregulated in response to increased production of 
endothelin- 1,which is regulated at the transcriptional level. (J Vasc Surg 1997;26:61-9.) 
Worldwide, the prevalence of varicose veins varies 
considerably but has been reported to be as high as 
64% in some Western populations, a In the United 
States, varicose veins have an estimated prevalence of 
20% to 57% and impose both a hea W case load and 
financial burden on health care systems. 2-4 The un- 
derlying cause of varicose veins is unclear. The hy- 
pothesis that varicosities develop only as a conse- 
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quence of valvular failure is countered by a number 
of clinical and experimental observations, s Current 
evidence suggests that a combination of environ- 
mental and hereditary factors leads to the develop- 
ment of biochemical, structural, and functional ab- 
normalities within veins that develop varicosities. 6,7 
For example, varicose veins have elevated collagen 
and elastin content, s 9 adrenergic defects, TM 12 enzy- 
matic abnormalities, ~3d5 altered eicosanoid produc- 
tion, 16'17 and endothelial ccll dysfunction. 11,18,19 
Previous results from our laboratory demonstrated 
that the content of the endothelium-derived peptide 
endothelin-1 is elevated in primary varicose veins, 
but the contractile response to endothelin-1 is di- 
minished, is Because ndothelin-1 is a smooth mus- 
cle mitogen in addition to being a potent vasocon- 
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Table I. Clinical data 
Primary 
Control varicosity 
Patients 16 13 
Mean age (yr) 66 52 
Sex 
Female 3 (19%) 6 (46%) 
Male 13 (81%) 7 (54%) 
Family history of W 0 9 (69%) 
Prior deep venous thrombosis 0 0 
Diabetes 5 (31%)* 0 
*Four required insulin. 
strictor, it may contribute to the pathogenesis of
varicose disease. The actions of endothelin-1 as mi- 
togens, as vasoconstrictors, or as both of these de- 
pends on the specific endothelin-receptor subtypes 
within the target tiSSUe. 20'21 Experiments were there- 
fore designed to extend previous findings by identi- 
fying and defining the involvement of specific endo- 
thelin receptor subtypes and the production of 
endothelin at the transcriptional level in varicose and 
nonvaricose human saphenous veins. 
METHODS 
Tissue procurement. Saphenous veins were col- 
lected from patients without primary varicosity who 
were undergoing arterial reconstruction (coronary or 
lower extremity grafts). Primary varicose vein (VV) 
tributaries of the greater saphenous vein and seg- 
ments of the proximal greater saphenous vein (SV) 
from the same patient were collected from patients 
who were undergoing stripping of the saphenous 
vein and resection of primary varicose veins, as previ- 
ously described.18 None of the patients had deep vein 
thrombosis at the time of surgery, nor did they have a 
history of deep vein thrombosis. Clinical and demo- 
graphic haracteristics ofpatients from whom tissues 
were collected are summarized in Table I. 
Organ chamber studies. Human veins col- 
lected during operations werc immersed in Krebs 
solution and transported to the research laborato~¢. 
Veins were immediately cut into rings, and half were 
mechanically denuded ofendothelium bygently roll- 
ing with watchman's forceps. Rings were suspended 
between a fixed stirrup and force transducer for mea- 
surement of isometric force in organ chambers filled 
with a modified Krebs-Ringer bicarbonate solution 
(control solution, in mmol/L: NaCI, 118.3; KC1, 
4.7; CaCl 2, 2.5; MgSO 4, 1.2; KH2PO 4, 1.2; 
NaHCO 3, 25.0; calcium disodium edetate, 0.026; 
glucose, 11.1; and aerated with 95% oxygen/5% car- 
bon dioxide, pH 7.4, 37 ° C). Each ring was 
stretched to the optimal point on its length-tension 
curve, as determined by tension developed to 20 
mmol/L KCI at each level of stretch. Once the opti- 
mal tension was set, 60 mmol/L KC1 was added to 
each bath to determine maximal response to KC1. 
Cumulative concentration-response curves to the 
nonselective endothelin receptor agonist endothe- 
lin-1 (10 -n to 10 -7 mol/L) or to the endothelin-B 
selective agonist sarafotoxin S6c (10 -n to 10 -7 
mol/L) were then obtained. Each ring was exposed 
to only one endothelin agonist. Rings from varicose 
vein tributaries and saphenous veins from the same 
patient were studied in parallel. 
Receptor binding membrane preparation. 
Freshly frozen veins with endothelium were pulver- 
ized in liquid nitrogen and 500 mg of the powdered 
tissue homogenized in 5 ml ice-cold membrane 
buffer (in mmol/L: sucrose, 25; MgCI 2, 3; ethyl- 
enediamine t traacetic a id (EDTA), 1; phenylmeth- 
ylsulfonyl, 0.5; Tris-HC1, 50; plus 1 tablet Complete 
(Boerhinger Mannheim) protease inhibitor cocktail 
per 50 ml buffer, pH 7.4) for 10 seconds using a 
Tekmar tissue homogenizer (Tekmar, Cincinnati) at 
full speed. The homogenate was centrifuged at 
2000g for 15 minutes at 4 ° C. The supernatant was 
collected and filtered through a212 b~m nylon screen 
and set aside on ice. The pellet was resuspended in 
3.5 ml membrane buffer and homogenized with the 
Tekmar for 10 seconds at full speed. The homoge- 
hate was centrifuged at 2000g for 15 minutes at 
4 ° C, and the resulting supernatant was added to the 
initial supernatant after passing through a 212 ~m 
nylon screen. The pellet was discarded. The solution 
was centrifuged at 40,000g for 30 minutes at 4 ° C 
and the supernatant discarded. The pellet was resus- 
pended in 575 bd membrane buffer using a sonic 
dismembrator (Fisher, Model 300, Pittsburgh) for 
approximately 10 seconds. A 50 ~1 aliquot was im- 
mediately collected for use in determining protein 
concentration using bicinchoninic acid protein assay 
reagent (Pierce, Rockford, I11.) with bovine serum 
albumin as standard. The remaining membrane sus- 
pension was immediately aliquoted (5 × 100 >1) and 
stored at -76 ° C for one day before diluting for use 
in binding experiments. 
Competition binding experiments were per- 
formed in duplicate using 4 ~g membrane protein 
with 12q-endothelin-1 (23 pmol/L) plus increasing 
concentrations (0 to 10 -7 mol/L) of unlabeled en- 
dothelin-1, endothelin-3, orsarafotoxin S6c in a final 
volume of 200 Izl binding buffer of the following 
composition: Tris-HCl, 50 retool/L; bovine serum 
albumin, 0.4%; bacitracin, 0.1%; phenylmethylsulfo- 
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nyl, 0.5 mmol/L;  MgC12, 5 retool/L; MnC12, 25 
mmol/L;  EDTA, 1 mmol/L;  plus one tablet Com- 
plete protease inhibitor cocktail per 50 ml buffer; pH 
7.4. Bound and free ligands were separated using a 
Skatron cell harvester (Skatron Instruments Inc., 
Sterling, Va.). With this device, the contents of the 
reaction chamber are rapidly rinsed (50 mmol /L  
Tris-HC1 buffer, pH 7.4) and immediately vacuum- 
filtered through a I gm retention glass filtermat. 
Radioactivity retained on the filters was counted on a 
gamma counter (Becl~anan Gamma 4000, Fullerton, 
Calif.). The specific activity of label (125I-endothe- 
lin-1) was 2000 Ci/nmol and was diluted such that 
50 Ixl yielded 20,000 cpm (23 pmol/L,  final concen- 
tration). An incubation time of 3 hours at 25 ° C was 
determined inpreliminary studies to result in equilib- 
rium for 125I-endothelin-1 binding (data not 
shown). Nonspecific binding was determined from 
nonlinear curve fitting as described in data analysis, 
but was originally estimated in parallel incubations 
containing the same without competitor plus 1 
txmol/L unlabeled endothelin- 1.The maximal num- 
ber of binding sites (Bmax) and inhibition constants 
(Ki) were calculated using nonlinear curve-fitting. 
The number of binding sites was determined by 
statistically comparing the curve-fits for one and two 
binding sites. 
Reverse transcriptase-polymerase chain reaction 
(RT-PCR). A random primed cDNA library was 
prepared using 1 ixg total RNA with SuperScript II
reverse transcriptase according to the manufacturer's 
directions (Gibco-BRL, N.Y.). The reaction was ter- 
minated by incubating at 70 ° C for 15 minutes fol- 
lowed by rapid chilling on ice. RNase H was added, 
and the mixture was allowed to incubate for 20 
minutes at 37 ° C. The resulting cDNA was amplified 
by combining 2 Ixl of the cDNA mixture in a PCR 
tube containing 0.2 mmol /L  each of dATP, dGTP, 
dTTP, and dCTP, 0.4 mmol /L  of upstream and 
downstream primers, 2 mmol /L  of MgC12, 2.5 U 
Tag polyrnerase (Promega), and PCR buffer to a final 
volume of 50 Ixl. The cDNA was amplified in a 9600 
Perldn Elmer cetus thermal cycler with [3-actin as an 
internal control. The thermal profile for a single cycle 
was as follows: denaturation at95 ° C for 1 minute, 
annealing at 56 ° C for 1 minute, extension at 72 ° C 
for 1.5 minutes, and a final extension at 72 ° C for 7 
minutes. The number of cycles was chosen to be 
within the logarithmic linear phase of the amplifica- 
tion curve (30 cycles for preproendothelin; [3-actin 
probe added at cycle 7 for a total of 23 cycles). 
The 5' primer for preproendothelin-1 consisted 
of 30 base pairs ( 157 to 186): TGCTCCTGCTCG- 
TCCCTGATGGATAAAGAG, and 3' primer of 27 
base pairs (592 to 618): GGTCACATAACGCT- 
CTCTGGAGGGCTT. The [3-actin probe consisted 
of a 5' primer of 20 base pairs (154 to 173): 
CCCAGGCACCAGGGCGTGAT, and 3' primer of 
20 base pairs (396 to 415): TCAAACATGATCT- 
GGGTCAT. 
The PCR reaction products were separated by 
agarose gel electrophoresis and photographed. Neg- 
atives were scanned and analyzed using an imaging 
computer program, and the preproendothelin-1 
DNA was normalized to its corresponding J3-actin 
DNA. 
Data analysis. For all studies, SVs and VVs were 
collected from the same patients, whereas control 
veins were from separate patients. All data are ex- 
pressed as mean + SEM; n equals the number of 
patients from whom veins were taken. For organ 
chamber studies, data are expressed as absolute in- 
crease in grams of tension. Maximal tensions, area 
under the tension curve, and concentrations produc- 
ing half-maximal response (ECs0) were calculated for 
individual concentration-response curves, and the 
means of these values were compared using one-way 
analysis of variance. If a significant F value was ob- 
tained, a Bonferroni post hoc test was used to com- 
pare means while controlling for multiple compari- 
sons. For all statistical tests, only those differences 
with a p value less than 0.05 were considered signifi- 
cant. 
Receptor binding studies were performed in du- 
plicate, and the average was used as a single value in 
data analysis. The maximal number of receptors 
(B .... ) and inhibition constants (Ki) were calculated 
from specific binding using the nonlinear curve-fit- 
ting computer program Ligand. 22 Single versus two- 
site models were selected using the residual variance 
of an F test, whereby a one-site model was deemed 
best unless the p value was less than the critical value 
of 0.05. B .... and Ki values were compared by paired 
t test for veins taken from the same patients but 
otherwise were compared by a one-way analysis of 
variance with a Bonferroni post hoc test. 
Drugs and chemicals. Human endothelin-1 
and endothelin-3 were obtained from Peptides Inter- 
national (Louisville). Sarafotoxin S6c was obtained 
from Phoenix Pharmaceuticals (Mountain View, 
Calif.). Human (3-[12sI]iodotyrosyl) endothelin-1 
was obtained from Amersham (Arlington Heights, 
Ill.). All other reagents were obtained from Sigma 
Chemical Co. (St. Louis). All concentrations are ex- 
pressed as the final molar (tool/L) concentration i  
the organ bath or incubation solution. 
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Fig. 1. Increases in tension to KC1 (60 mol/L) in rings 
with (left bars) or without (right bars) endothelium. Con- 
tractions were significantly greater in control veins (solid 
bars, n = 5) compared with VVs (open bars, n = 6) but not 
SVs (hatched bar, n = 6). There were no significant differ- 
ences to KCI contractions in veins with endothelium versus 
those without. For each patient he responses of two rings 
with or two rings without endothelium were averaged to 
provide a single value for that patient. *Significant differ- 
ence compared with control veins (p < 0.05 analysis of 
variance, Bonferroni post hoc test). 
RESULTS 
Organ chambers. Contractions to potassium 
chloride (KC1, 60 mmol /L)  in veins with or without 
endothelium were significantly greater in control 
veins versus VVs; contractions in SVs were greater 
than in VVs but less than in control veins (Fig. 1). 
Endothelin-1 (10 -ll to 10 -7 mol /L)  caused a 
concentration-dependent co raction of all veins ei- 
ther with or without endothelium (Fig. 2, top pan- 
els). Both maximal contractions and area under the 
endothelin-1 contraction curves were significantly 
greater in control veins compared with either SVs 
or VVs, either with or without endothelium (Fig. 
2, top panels, and Table II). Responses to endothe- 
lin-1 were significantly shifted rightward in both 
SVs and VVs compared with control rings either 
with or without endothelium (Fig. 2, top panels, 
and Table II). Maximal response, total area under 
the response curve, and ECs0 were not signifi- 
cantly different between SVs and VVs either with 
or without endothelium (Fig, 2, top panels, and 
Table II). 
Sarafotoxin $6c (10 -lI to 10 -7 tool /L)  caused a 
concentration-dependent contraction that dimin- 
ished at higher concentrations in all veins either with 
or without endothelium (Fig. 2, bottom panels). 
Maximal contractions and area under the sarafotoxin 
$6c contraction curves were greater in control veins 
compared with either SVs or VVs; however, this 
difference was not statistically significant (Fig. 2, bot- 
tom panels, Table II). The sensitivity of veins to 
sarafotoxin $6c was significantly different among all 
three vein groups: control veins were the most sensi- 
tive, followed by SVs, with VVs being the least sensi- 
tive (Fig. 2, bottom panels, Table II). 
Receptor  binding. Binding of ~25I-endothe- 
l ind was inhibited in a concentration-dependent 
manner by unlabeled endothelin-1, endothelin-3, or 
sarafotoxin $6c. For all vein groups studied, nonlin- 
ear regression analysis of competitive inhibition of 
t2~I-endothelin-1 best fit a one-site binding model 
for endothelin-1 and sarafotoxin $6c and a two-site 
model for endothelin-3 (Fig. 3). 
The total number of endothelin-1 binding sites 
was higher in control veins compared with either SVs 
or VVs alone, but this difference was not statistically 
significant (Fig. 4, top panel). However, compared 
with the combination of SVs and VVs, the total 
number of  endothelin-1 binding sites was signifi- 
cantly greater in control veins (Fig. 4, top panel). 
Binding affmities for endothelin-1 were not signifi- 
cantly different among all vein groups (-log M, Ki = 
i0.32 + 0.03 for controls, n = 8; 10.34 ± 0.06 for 
SVs, n = 4; 10.18 ± 0.05 for VVs, n = 4). 
For the displacement of 12SI-endothelin-1 by en- 
dothelin-3, neither the total number of binding sites 
(Bmax) nor the binding affinities (Iq-) for the low- 
affinity binding site (ETA receptor) differed between 
vein groups (Figs. 3 and 4, middle panels). However, 
for the high-affinity endothelin-3 binding site (ETB 
receptor), the total number of  binding sites was 
greatest in control veins, lesser in SVs, and lesser still 
in VVs (Figs. 3 and 4, middle panels). These differ- 
ences alone were not statistically significant; how- 
ever, Bma x from the combination of SVs with VVs 
was significantly lower compared with control veins 
(high-affinity B. . . .  387.4 ± 56.4 fmol /mg protein 
for controls, n = 8; 240.1 ± 37.5 fmol /mg protein 
for SVs and VVs combined, n = 8; p < 0.05 by 
unpaired t test). For both the high- and low-affinity 
binding sites, binding affinities for endothelin-3 were 
not significantly different among all vein groups 
(high-affinity site: - log M I<~ = 9.67 ± 0.22 for 
controls, n = 8; 9.29 ± 0.10 for SVs, n = 4; 10.34 -+ 
0.50 for VVs, n = 4; low-affinity site: 7.72 +- 0.20 for 
controls, n = 8; 7.61 ± 0.16 for SVs, n = 4; 7.93 ± 
0.34 for VVs, n = 4). 
The total number of binding sites determined 
from the displacement of ~25I-endothelin-1 by the 
specific endothelin-B receptor agonist sarafotoxin 
$6c tended to be less in SVs and VVs compared with 
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Fig. 2. Cumulative concentration-response curves for endothel in-1 (top panels) and sarafo- 
toxin $6c (lower panels) in venous rings with (left panels) or without endothel ium &ightpanels). 
Concentrat ion-dependent  increases in tension to both  endothel in-1 and sarafotoxin $6c were 
significantly greater in control veins (filled triangle) compared with either SVs (filled circle) or 
VVs (open circle). *Statistical significance in both total area under concentration-response curve 
and maximal response in control versus either SVs or VVs; p < 0.05 analysis of variance, 
Bonferroni post hoc. ECs0 was not  different among groups for endothelin-1. However, the 
ECs0 for sarafotoxin $6c was significantly shifted rightward in either SVs or VVs compared with 
control veins. The ECso for sarafotoxin $6c was also significantly shifted rightward in VVs 
compared with SVs. 
Table II. Maximal tensions and ECs0 for endothelin agonists in human saphenous veins with and 
without endothelium 
With endothdium 
M.x O) ECso , - log M 
Without endothelium 
Max (g) ECso , - logM 
Endothelin- 1 
Control (n = 5) 
SV (n = 6) 
VV (n = 6) 
Sarafotoxin Sbc 
Control (n = 5) 
SV (n = 6) 
W (n = 6) 
6.26 _+ 0.94 
2.35 _+ 0.66* 
1.88 _+ 0.78* 
1.68 _+ 0.40 
1.07 +_ 0.27 
0.93 _+ 0.38 
8.37 _+ 0.08 
7.42 _+ 0.04* 
7.64 _+ 0.07* 
9.96 _+ 0.03 
8.70 _+ 0.01" 
8.52 _+ 0.04~ 
7.43 _+ 1.77 
2.40 _+ 1.04" 
2.15 _+ 0.57* 
2.20 +_ 0.67 
0.95 _+ 0.32 
0.78 _+ 0.40 
8.57 -+ 0.10 
7.60 +- 0.08* 
7.60 -+ 0.06* 
9,93 -+ 0.05 
8.92 -+ 0.04* 
8.20 _+ 0.02[ 
*p < 0.05 compared with controls. 
tP < 0.05 compared with SVs. 
Max, maximal tensions. 
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Fig. 3. Competitive inhibition ofl25I-endothelin-1 bind- 
ing by unlabeled endothelin-1 (top panel), endothelin-3 
(middle panel) or sarafotoxin $6c (lower panel) in mem- 
brane protein homogenates prepared from either greater 
saphenous veins of patients undergoing coronary artery or 
femoropopliteal bypass procedures (filled triangle, con- 
trois, n = 8), greater saphenous veins from patients under- 
going vein stripping for primary varicosity (filled circle, 
SVs, n = 4), or primary varicose vein tributaries of the 
greater saphenous vein (open circle, VVs, n = 4). Nonlinear 
regression analysis for 12H-endothelin-1 inhibition was sig- 
nificant for a one-site binding model for endothelin-1 and 
sarafotoxin $6c and a'two-site binding model for endothe- 
lin-3. Binding affinities (K~) did not differ among groups 
for any of the endothelin ligands. 
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Fig. 4. Number ofendothelin binding sites (B ..... ) deter- 
mined by nonlinear regression analysis of competitive inhi- 
bition of 12SI-endothelin- 1 binding by unlabeled endothe- 
lin- 1 (top panel), endothelin-3 (middle panel), or sarafotoxin 
$6c (lower panel). In middle panel, Bma x values for the high 
affinity binding site are represented asETB (solid bar) and 
for the low-affinity binding site as ETA (open bar). *Signif- 
icantly higher total number of binding sites in control 
compared with the combination of SVs and VVs (p < 0.05 
unpaired t test). 
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control veins but was not statistically significant 
(Figs. 3 and 4, lower panels). Binding affinities also 
were not statistically different among all vein groups 
(-log M, Iq = 7.77 -+ 0.09 for controls, n = 8; 
7.34 _+ 0.48 for SVs, n = 4; 7.39 + 0.09 for VVs, 
n= 4). 
RT -PCR.  Band densities for preproendothelin 
mKNA normalized to J3-actin mRNA band dhnsities 
were greater in VVs compared with either SVs or 
control veins (Fig. 5). This difference was not statis- 
tically significant but was reproducible in Northern 
blots normalized to cyclophilin (data not shown). 
D ISCUSSION 
Results from this study confirm earlier findings 
that contractions to endothelin-1 are diminished in 
varicose veins. Contractions to endothelin-1 were 
also diminished in the greater saphenous veins from 
patients with primary varicose disease but to lesser 
extent han in the varicose tributary. Decreased con- 
tractions ofvaticose veins probably are in part a result 
of a loss of contractile function in the varicose veins. 
Indeed, contractions of the varicose veins are also 
reduced to direct depolarization with KC1 (Fig. 1) 
and other vasoactive agonists, including norepineph- 
ring serotonin, histamine, and passive stretch. 12,23,24 
However, loss of contractile protein may represent 
only one component of the functional changes asso- 
ciated with varicose disease. In addition to adecrease 
contraction to endothelin-1, which stimulates both 
endothelin-A and endothelin-B receptors, contrac- 
tions to sarafotoxin $6c were decreased. Sarafotoxin 
$6c selectively stimulates endothelin-B receptors. 
Receptor binding studies indicated that the number 
but not the affinit T of endothelin-B receptors was 
diminished in varicose veins. Moreover, changes in 
contractions to sarafotoxin $6c were not the result of 
release of endothelium-derived relaxing factors in 
response to stimulation ofendothelin-B receptors on 
the endothelium because mechanical removal of the 
endothelium did not abrogate the contractile differ- 
ences. Collectively then, these data suggest hat as 
veins become varicosed, there is specific loss of endo- 
thelin-B receptors and the associated contractile re- 
sponses. 
The concentration-response curve to sarafotoxin 
$6c in human varicose veins was biphasic. That is, as 
concentrations ofsarafotoxin $6c increased, contrac- 
tions increased then decreased. This biphasic re- 
sponse is consistent with responses of veins from 
other animals. 2s-27 It is unclear at this time whether 
the decline in contractions represents desensitization 
or internalization of receptors 28 or stimulation of a 
subclass ofendothelin-B receptors. 27,29 Regardless of 
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Fig. 5. Band densities for preproendothelin mRNA fi'om 
RT-PCR of total RNA from either control (n = 6), greater 
saphenous veins from patients undergoing vein stripping 
for primary varicosity (n = 3), or primary varicose vein 
tributaries of the greater saphenous vein (n = 3). The 
agarose gel of the electrophoretically separated PCR prod- 
ucts is pictured in inset: from right to left, lane I is a weight 
standard, lanes 2 to 7 are from control, lanes 8 to 10 are 
from SVs, lanes 11 to 13 are from VVs, and lane 14 is 
duplicate weight standard. Upper bands are mRNA for 
preproendothelin (461 base pairs), and lower bands are 
mRNA for the internal control ~-actin (261 base pairs). 
Preproendothelin mRNA tended to be higher in VVs; 
however, this difference was not statistically significant. 
the exact mechanism, the fact that the characteristic 
decline in contractions to saratbtoxin $6c remains in 
varicose veins suggests that these mechanisms remain 
intact as varicose disease develops. As the desensitiza- 
tion mechanism is further characterized, it may offer 
new insights into intracellular processes that remain 
unaffected in varicose disease. 
The functional importance of decreased number 
of endothelin-B receptors in varicose veins may not 
reside only in stimulation of contractions. Stimula- 
tion of endothelin-B receptors may regulate mito- 
genic properties of the endothelins in both vascular 
smooth muscle and endothelial cells. 2°~21,3° Thus it 
becomes attractive to speculate that changes in endo- 
thelin-B receptors coupled to mitogenic or secretory 
functions of the smooth muscle cells may parfcipate 
in the development of the structural abnormalities of 
varicose veins. 3>33 
In a previous tudy, endothelin-1 content of var- 
icose veins was greater than that of nonvaricose 
veins.18 Whether this increase in content of endothe- 
lin-1 was an artifact that resulted from significant 
differences in total protein content of varicose veins is 
unclear. However, results of the current study extend 
those of the previous study to examine mRNA for 
endothelin-1, a measure that is independent of total 
protein concentration. The results of the current 
study support hat the increase in endothelin-content 
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o f  varicose veins may be the results o f  increased 
transcription o f  the gene, as indicated by increases in 
mRNA for preproendothel in-1.  This observation 
does not  rule out  posttranscript ional regulat ion for 
product ion o f  endothel in-1 in varicose veins, how- 
ever. 
The increase in content /product ion /secret ion  o f  
endothel in-1 could account for the downregulat ion 
o f  the endothel in-B receptors. Exposure o fendothe-  
l in-receptors to excess l igand downregulates the 
number  of  endothel in receptors in other cells, a4-a6 It  
is unclear why endothel in-B but  not  endothel in-A 
receptors are downregulated in varicose veins. Other  
regulatory mechanism involving intracellular second 
messenger systems cannot be excluded at this time. 
A l imitat ion o f  the current study arises from the 
considerable variabil ity encountered with the use o f  
human tissue. Differences in receptor binding and 
RT-PGR were often l imited to strong trends that 
lacked statistical significance. This may reflect the 
varying degrees o f  severity o f  the disease. In addit ion, 
vascular-related diseases uch as diabetes in control  
patients may have affected results. Differences in an- 
esthesia, which was always general for control  pa- 
tients and usually (approximately 80%) epidural for 
patients with primary varicose disease, may also have 
contr ibuted to the variability o f  results, 
Whether  the morphologic ,  biochemical,  and 
functional changes associated with varicose veins me- 
diate the development ofvaricosit ies or merely repre- 
sent a secondary consequence of  the pathophysio-  
logic process remains a contentious issue. An 
important  f inding o f  the current study relates to the 
biochemical and functional changes associated with 
endothel in-1 and endothel in receptors in greater sa- 
phenous veins o f  patients with primary varicose dis- 
ease. These veins lack overt anatomical tortuosit ies 
characteristic o f  fully varicosed veins. The observa- 
tions support  the hypothesis that biochemical and 
functional abnormalit ies develop within the vein wall 
before the development o f  anatomical ly identif iable 
varicose veins. 
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